TransMedics (TMDX) is a buy for 2028, with strong revenue growth, improved margins, and limited dilution. Read here for more analysis.

The essential factor in the Dreyfus affair was that it was a story of Jews who felt that something like that could never ...

As 2026 approaches, the Bank of Japan (BOJ) finds itself in the uncomfortable position of a central bank whose warnings no ...

Discover why options market data suggests a lower crash risk for U.S. stocks than pundit surveys, and how to optimize asset ...

Boost your SQL interview readiness with these 35 carefully selected SQL Interview Questions and Answers. Includes real-world ...

The Ukrainian president opens the door to creating a demilitarized zone supervised by 'international forces' in the part of ...